NYSE:USNA

Stock Analysis Report

Executive Summary

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease.

Snowflake

Fundamentals

Flawless balance sheet with solid track record.


Similar Companies

Share Price & News

How has USANA Health Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.7%

USNA

-0.6%

US Personal Products

1.8%

US Market


1 Year Return

-32.2%

USNA

24.0%

US Personal Products

7.3%

US Market

Return vs Industry: USNA underperformed the US Personal Products industry which returned 24% over the past year.

Return vs Market: USNA underperformed the US Market which returned 7.3% over the past year.


Shareholder returns

USNAIndustryMarket
7 Day1.7%-0.6%1.8%
30 Day-1.2%-1.9%-0.7%
90 Day12.5%-1.8%0.06%
1 Year-32.2%-32.2%25.9%24.0%9.7%7.3%
3 Year-4.0%-4.0%42.2%34.9%46.3%36.9%
5 Year65.3%65.3%80.2%62.0%64.5%46.5%

Price Volatility Vs. Market

How volatile is USANA Health Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is USANA Health Sciences undervalued compared to its fair value and its price relative to the market?

37.3%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: USNA ($70.51) is trading below our estimate of fair value ($112.43)

Significantly Undervalued: USNA is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: USNA is good value based on its PE Ratio (15.4x) compared to the Personal Products industry average (19.2x).

PE vs Market: USNA is good value based on its PE Ratio (15.4x) compared to the US market (17.7x).


Price to Earnings Growth Ratio

Low PEG Ratio: USNA's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: USNA is overvalued based on its PB Ratio (4.2x) compared to the US Personal Products industry average (3.7x).


Next Steps

Future Growth

How is USANA Health Sciences forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-1.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: USNA's earnings are forecast to decline over the next 3 years (-1.1% per year).

Earnings vs Market: USNA's earnings are forecast to decline over the next 3 years (-1.1% per year).

High Growth Earnings: USNA's earnings are forecast to decline over the next 3 years.

Revenue vs Market: USNA's revenue is expected to decline over the next 3 years (-0.4% per year).

High Growth Revenue: USNA's revenue is forecast to decline over the next 3 years (-0.4% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if USNA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has USANA Health Sciences performed over the past 5 years?

5.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: USNA's earnings have grown by 5.3% per year over the past 5 years.

Accelerating Growth: USNA's earnings growth over the past year (35%) exceeds its 5-year average (5.3% per year).

Earnings vs Industry: USNA earnings growth over the past year (35%) exceeded the Personal Products industry 21%.


Return on Equity

High ROE: USNA's Return on Equity (28.4%) is considered high.


Return on Assets

ROA vs Industry: USNA has a higher Return on Assets than the Personal Products industry average last year.


Return on Capital Employed

ROCE Improving: USNA's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is USANA Health Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: USNA's short term assets ($348.8M) exceeds its short term liabilities ($128.8M)

Long Term Liabilities: USNA's short term assets (348.8M) exceeds its long term liabilities (19.5M)


Debt to Equity History and Analysis

Debt Level: USNA is debt free.

Reducing Debt: USNA has no debt compared to 5 years ago when its debt to equity ratio was 0.09%.

Debt Coverage: USNA has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: USNA has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: USNA has a high level of physical assets or inventory.

Debt Coverage by Assets: USNA's debt is not covered by short term assets (assets are -9.8173686802073E+16x debt).


Next Steps

Dividend

What is USANA Health Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.7%industryaverage1.5%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate USNA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate USNA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if USNA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if USNA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of USNA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of USANA Health Sciences's salary, the management and board of directors tenure and is there insider trading?

2.9yrs

Average management tenure


CEO

Kevin Guest (56yo)

2.9yrs

Tenure

US$2,919,177

Compensation

Mr. Kevin G. Guest has been the Chief Executive Officer of USANA Health Sciences, Inc. since November 23, 2016. Mr. Guest served as Co-Chief Executive Officer of USANA Health Sciences Inc., from August 4,  ...


CEO Compensation Analysis

Compensation vs. Market: Kevin's total compensation ($USD2.92M) is about average for companies of similar size in the US market ($USD4.07M).

Compensation vs Earnings: Kevin's compensation has increased by more than 20% in the past year.


Management Age and Tenure

2.9yrs

Average Tenure

53.5yo

Average Age

Experienced Management: USNA's management team is considered experienced (2.9 years average tenure).


Board Age and Tenure

15.8yrs

Average Tenure

75.5yo

Average Age

Experienced Board: USNA's board of directors are seasoned and experienced ( 15.8 years average tenure).


Insider Trading

Insider Buying: USNA insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$288,79313 Sep 19
Robert Anciaux
EntityIndividual
Role
Member of the Board of Directors
Director
Shares4,018
Max PriceUS$71.87
SellUS$21,91230 Jul 19
Gilbert Fuller
EntityIndividual
Role
Lead Director
Lead Independent Director
Shares329
Max PriceUS$66.60
SellUS$24,41610 May 19
Gilbert Fuller
EntityIndividual
Role
Lead Director
Lead Independent Director
Shares282
Max PriceUS$86.58
SellUS$31,07613 Feb 19
Gilbert Fuller
EntityIndividual
Role
Lead Director
Lead Independent Director
Shares282
Max PriceUS$110.20
SellUS$418,69011 Feb 19
Robert Anciaux
EntityIndividual
Role
Member of the Board of Directors
Director
Shares3,500
Max PriceUS$120.10
SellUS$29,86608 Feb 19
Frederic Winssinger
EntityIndividual
Shares282
Max PriceUS$105.91
SellUS$35,16813 Dec 18
Feng Peng
EntityIndividual
Shares282
Max PriceUS$124.71
SellUS$33,88229 Nov 18
Feng Peng
EntityIndividual
Shares282
Max PriceUS$120.15
SellUS$43,37909 Nov 18
Walter Noot
EntityIndividual
Role
Chief Information Officer
Chief Information Officer
Shares363
Max PriceUS$119.50
SellUS$32,01807 Nov 18
Gilbert Fuller
EntityIndividual
Role
Lead Director
Lead Independent Director
Shares282
Max PriceUS$113.54
SellUS$43,28631 Oct 18
G. Hekking
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares387
Max PriceUS$111.85
SellUS$32,27731 Oct 18
Frederic Winssinger
EntityIndividual
Shares282
Max PriceUS$114.46
SellUS$32,39931 Oct 18
P. Foukas
EntityIndividual
Role
Chief Legal Officer
Chief Legal Officer
Shares291
Max PriceUS$111.34

Ownership Breakdown


Management Team

  • Myron Wentz (78yo)

    Founder & Chairman of the Board

    • Tenure: 27.8yrs
  • Walter Noot (53yo)

    Chief Information Officer

    • Tenure: 2.8yrs
    • Compensation: US$1.11m
  • Rob Sinnott (54yo)

    Chief Scientific Officer

    • Tenure: 3.2yrs
  • Kevin Guest (56yo)

    CEO & Director

    • Tenure: 2.9yrs
    • Compensation: US$2.92m
  • Doug Hekking (49yo)

    Chief Financial Officer

    • Tenure: 2.4yrs
    • Compensation: US$1.13m
  • John Cuomo

    Executive Director of Product Development & Technology

    • Tenure: 6.8yrs
  • Jim Brown (50yo)

    President & COO

    • Tenure: 2.9yrs
    • Compensation: US$1.71m
  • David Mulham (59yo)

    Chief Sales Officer

    • Tenure: 2.7yrs
    • Compensation: US$1.16m
  • P. Foukas (43yo)

    Chief Legal Officer

    • Tenure: 0yrs
  • Patrique Richards

    Head of Investor Relations

    • Tenure: 0yrs

Board Members

  • Myron Wentz (78yo)

    Founder & Chairman of the Board

    • Tenure: 27.8yrs
  • Gil Fuller (78yo)

    Lead Independent Director

    • Tenure: 0yrs
    • Compensation: US$249.16k
  • Peggie Pelosi

    Independent Director

    • Tenure: 0.8yrs
    • Compensation: US$2.50k
  • Robert Anciaux (73yo)

    Director

    • Tenure: 23.3yrs
    • Compensation: US$217.21k
  • Kevin Guest (56yo)

    CEO & Director

    • Tenure: 2.9yrs
    • Compensation: US$2.92m
  • Christine Wood

    Member of Scientific Advisory Council

    • Tenure: 0yrs
  • Monica Lewis

    Member of Scientific Advisory Council

    • Tenure: 0yrs
  • Peter Rugg

    Chairperson of Scientific Advisory Council

    • Tenure: 15.8yrs
  • Bart Moore

    Member of Scientific Advisory Council

    • Tenure: 0yrs
  • Heather Tick

    Member of Scientific Advisory Council

    • Tenure: 0yrs

Company Information

USANA Health Sciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: USANA Health Sciences, Inc.
  • Ticker: USNA
  • Exchange: NYSE
  • Founded: 1992
  • Industry: Personal Products
  • Sector: Household
  • Market Cap: US$1.569b
  • Shares outstanding: 22.26m
  • Website: https://www.usana.com

Number of Employees


Location

  • USANA Health Sciences, Inc.
  • 3838 West Parkway Boulevard
  • Salt Lake City
  • Utah
  • 84120
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
USNANYSE (New York Stock Exchange)YesCommon StockUSUSDNov 1994
USJDB (Deutsche Boerse AG)YesCommon StockDEEURNov 1994

Biography

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nut ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 23:44
End of Day Share Price2019/10/17 00:00
Earnings2019/06/29
Annual Earnings2018/12/29


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.